Inside the Market of Emerging Biotechs

For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.


  • In a year with few biotech IPOs, ‘crossover’ financings are hard to find
  • Early-stage biotech funding in 2023 lagging behind previous years’ pace
  • F-Prime’s Ketan Patel on ‘reverse ageism’ in biotech and investing in a downturn

Request Free!